Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Birabresib||Preclinical - Cell culture||Actionable||In a preclinical study, Birabresib (OTX015) inhibited growth of a variety of tumor cell lines in cell culture (Mol Cancer Ther November 2013 12; C244).||detail...|
|Unknown unknown||Advanced Solid Tumor||not applicable||Birabresib||Phase Ib/II||Actionable||In a Phase Ib trial, Birabresib (OTX015) demonstrated favorable safety and resulted in partial response in 7% (3/42) and stable disease in 60% (25/42) of patients with non-small cell lung cancer, prostate cancer, or NUT midline carcinoma, with all of the responses occurring in NUT midline carcinoma patients (PMID: 29733771; NCT02259114).||29733771|